Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 cr
Global investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a 3 percent stake in Anthem Biosciences. The deal, valued at Rs 1,275 crore, saw promoter Aruna Ganesh exit the company. This significant transaction reshapes the promoter's holding in the integrated Contract Research, Development and Manufacturing Organisation.
Stocks in news: IFCI, Tata Motors, General Insurance Corp, Corona Remedies, HFCL
Markets extended their winning streak for the fourth consecutive session, driven by favorable global cues and sustained sector-wide buying. The Nifty reclaimed the 24,000 mark, approaching the 100-day EMA near 24,150. Stocks like IFCI, Tata Motors, and HFCL are in focus due to significant news developments, including IPO filings, turnaround projections, and major order wins.
HDFC MF, ADIA among buyers as Sepia Investments offloads Rs 749 crore in Corona Remedies via block deal
Sepia Investments and Anchor Partners sold shares worth about Rs 777 crore in Corona Remedies through block deals. HDFC Mutual Fund emerged as the largest buyer, while several institutional investors, including Aberdeen entities, ADIA, Invesco and WhiteOak, also accumulated stakes.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
7 most valued firms' mcap eroded ₹1.25 trn last week, RIL took biggest hit
The combined market valuation of seven of the top-10 most-valued firms eroded by Rs 1.25 lakh crore last week, with Reliance Industries taking the biggest hit, in-line with a bearish trend in equities. Last week, the BSE benchmark Sensex declined 532.4 points, or 0.71 per cent, and the NSE Nifty dipped 181.05 points, or 0.76 per cent. "Persistent FII selling remained the key drag on market sentiment despite supportive developments such as cooling crude oil prices and a recovery in the rupee against the US dollar. Concerns regarding the pace of monsoon advancement also weighed on investor confidence," Santosh Meena, Head of Research at Swastika Investmart Ltd, said. From the top-10 pack, Reliance Industries, Bharti Airtel, Tata Consultancy Services (TCS), Bajaj Finance, Larsen & Toubro, Life Insurance Corporation of India (LIC) and Hindustan Unilever faced erosion from their valuation, while HDFC Bank, ICICI Bank, and State Bank of India were the gainers. The market valuation of ...

Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.
Stocks to buy today: Sudeep Pharma, Rubicon Research, ICICI Prudential AMC
Stocks to buy today: Aakash Shah of Choice Broking has recommended buying three stocks today - Rubicon Research, Sudeep Pharma, and ICICI Prudential Asset Management.
Indoco Remedies climbs after Baddi plant secures EU GMP certification; ICICI Prudential MF buys 1.47% stake
Indoco Remedies rose 4.04% to Rs 211.60 after the company said its oral solid dosage formulations facility at Baddi, Himachal Pradesh, received European Union Good Manufacturing Practice (EU GMP) certification from the German Health Authority (Berlin
Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmer
Indian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their effect on peace deal hopes. Broader markets are performing better. India VIX, a volatility measure, dropped. Top Sensex losers included HDFC Bank and Infosys. Sun Pharma shares led gains. Midcap and smallcap indices saw small gains.